General
Preferred name
Vitamin A
Synonyms
RETINOL ()
retinol acetate ()
all-trans-Retinol ()
Vitamin A1 ()
Alphalin ()
Aquasol A ()
Arovit ()
Retinol palmitate ()
Retinol (vit a) ()
Vitamin a ()
Retinol Acetate ()
NSC-122759 ()
Vitamin A 1 ()
Nepalm ()
Oleovitamin A ()
Vitamin A Solubilized ()
Vitamin A Oil ()
Ro-A-Vit ()
ALK-001 ()
GILDEURETINOL ()
P&D ID
PD001451
CAS
68-26-8
11103-57-4
22737-96-8
13123-33-6
Tags
available
drug candidate
drug
Approved by
FDA
First approval
1953
Drug indication
Night blindness
Kinetoplastids
Vitamin (anti-xerophthalmic)
Drug Status
nutraceutical
approved
investigational
vet_approved
Max Phase
4.0
1.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Retinol (vitamin A1) plays an essential role in (night) vision, normal bone and tooth development, reproduction, and is required for maintaining the integrity of skin and mucous membranes. It has antioxidant activity.
(GtoPdb)
TOXICITY
Acute toxicity (single ingestion of 7 500 RE or 25 000 IU per kg or more): Signs and symptoms may be delayed for 8 to 24 hours and include: increased intracranial pressure, headache, irritability, drowsiness, dizziness, lethargy, vomiting, diarrhea, bulging of fontanels in infants, diplopia, papilledema. Peeling of skin around mouth may be observed from 1 to several days after ingestion and may spread to the rest of the body.; Chronic, excessive ingestion (1 200 RE or 4 000 IU/kg daily for 6 to 15 months) may produce symptoms of pseudotumor cerebri, anorexia, weakness, arthralgias, bone pain, bone demineralization, dry skin, cracked lips, brittle nails, hair loss, splenomegaly, hepatomegaly, hypoplastic anemia, leukopenia, optic neuropathy, and blindness. Increased plasma concentrations of vitamin A occur but do not necessarily correlate with toxicity.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
0
Compound Sets
26
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
64
Molecular Weight
286.23
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
1
Aromatic Ring Count
0
cLogP
5.51
TPSA
20.23
Fraction CSP3
0.5
Chiral centers
0.0
Largest ring
6.0
QED
0.66
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Endogenous Metabolite
Retinol-binding protein
ALDH1A1, ALDH1A2, ALDH1A3, DHRS3, DHRS4, LRAT, NR2C2, RBP1, RBP3, RDH11, RDH12, RDH13, RDH14, RDH5, RDH8, RETSAT, RHO, RLBP1, RXRA, RXRB, RXRG
Pathway
Metabolic Enzyme/Protease
Vitamin
MOA
VA
1 Epidermal transglutaminase inhibitor
retinoid receptor ligand
Member status
virtual
Indication
cosmetic, acne vulgaris (AV), keratosis
Therapeutic Class
Vitamins
Source data
